Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 5/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19949377 | 1.00 | BACE1 (0.40) | BACE1BACE2USP30CACNA1GCACNA1B | |
| SCHEMBL19950334 | 0.93 | BACE1 (0.40) | BACE1BACE2USP30CACNA1GCACNA1B | |
| SCHEMBL24753989 | 0.93 | BACE1 (0.35) | BACE1BACE2USP30CACNA1GCACNA1B | |
| SCHEMBL29746567 | 0.86 | USP30 (0.37) | BACE1BACE2USP30CACNA1GCACNA1B | |
| SCHEMBL19960773 | 0.86 | USP30 (0.37) | BACE1BACE2USP30CACNA1GCACNA1B | |
| SCHEMBL24933896 | 0.86 | HTR2C (0.33) | BACE1BACE2CACNA1GCACNA1BCACNA1C | |
| SCHEMBL19948905 | 0.84 | ALDH1A1 (0.33) | — | |
| SCHEMBL18416939 | 0.81 | BACE1 (0.40) | BACE1BACE2USP30CACNA1GCACNA1B | |
| SCHEMBL30868978 | 0.80 | USP30 (0.40) | BACE1BACE2USP30CACNA1GCACNA1B | |
| SCHEMBL19960737 | 0.79 | USP30 (0.43) | BACE1BACE2USP30PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516059-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2024-02-06 | — | — | US | disclosed |
| US-11866426-B2 | Benzothiazole compounds and uses thereof | INCYTE CORPORATION (US) | 2024-01-09 | — | — | US | disclosed |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4119558-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Incyte Corporation (US) | 2023-01-18 | — | — | EP | disclosed |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220227752-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2022-07-21 | — | — | US | disclosed |
| EP-3510032-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORP (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11242343-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | BACE1 4244/4885BACE2 3852/4885USP30 3969/4885 |
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | BACE1 4244/4885BACE2 3852/4885USP30 3969/4885 |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | BACE1 4244/4885BACE2 3852/4885USP30 3969/4885 |
| US-11242343-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | BACE1 4244/4885BACE2 3852/4885USP30 3969/4885 |
| US-20220227752-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | BACE1 4244/4885BACE2 3852/4885USP30 3969/4885 |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, PDK2 | BACE1 4147/4885BACE2 3885/4885USP30 3819/4885 |
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | BACE1 4244/4885BACE2 3852/4885USP30 3969/4885 |
| US-11866426-B2 | Benzothiazole compounds and uses thereof | PDXK, PCK1, HIPK1 | BACE1 3836/4885BACE2 3319/4885USP30 1781/4885 |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | BACE1 4244/4885BACE2 3852/4885USP30 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.